Research Article

Intake of Novel Red Clover Supplementation for 12 Weeks Improves Bone Status in Healthy Menopausal Women

Anne Cathrine Thorup, Max Norman Lambert, Henriette Strøm Kahr, Mette Bjerre, and Per Bendix Jeppesen

1. Introduction

Menopause is a natural occurring part of life characterized by amenorrhea due to the cessation of the ovarian function causing reduced circulating estrogens levels. During and after menopause, an intense bone loss occurs which over time can lead to osteopenia. Osteopenia is often asymptomatic, generally presenting no or mild clinical symptoms until development of fractures and osteoporosis. Osteoporosis is a metabolic disorder, characterized by low bone mass and density, causing bone fragility and increased risk of bone fracture. The maintenance of bone homeostasis in mammals is influenced by estrogens and the decline in endogenous estrogen (especially 17β-estradiol) during and after menopause. It results in enhanced bone resorption accompanied by impaired bone formation, regeneration, and increase of fat tissue in the bone marrow [1, 2]. The treatment of choice to remedy and prevent osteoporosis and consequently occurrence of fractures was previously hormone replacement therapy (HRT) [3, 4]. However, in 2002 the first publication [5] from the Women's Health Initiative trial yielded statistically significant increases in cases of breast cancer and cardiovascular events in HRT-treated women. This prompted sudden changes to recommendations concerning HRT. Due to the critical risk-benefit profile, pharmacological treatment cannot be used in cases of low osteoporosis risk, and osteopenia itself is not a criterion for pharmacotherapy under current international guidelines [6].

A range of antiresorptive or anabolic options are available for the treatment of postmenopausal osteoporosis reducing...
the fracture risk [7]; however, the existing treatment program for osteoporosis is associated with a significant risk of adverse effects [8, 9]. It is of both medical and scientific interest to find alternative therapies that have a milder action which provide the same beneficial results and less adverse side effects.

Within the last decade the use of natural supplements has become more widespread in the search for viable alternatives to existing treatments [10–15]. A compelling alternative is phytoestrogens which have shown promising results as an alternative medicine. Phytoestrogens are secondary metabolites that can induce biological responses in vertebrates and can mimic or modulate the actions of endogenous oestrogens, usually by binding to the estrogen receptors (ERs) [16]. ERs are steroid receptors but are unique in their ability to interact with a variety of compounds [17]. Phytoestrogens are believed to work by binding to ERs (two subtypes exist, ERα and ERβ) on cell membranes, similar to the body’s own steroid oestrogens [18]. The ERβ is widely expressed in the body and the predominantly receptor in trabecular bone [19], but in the breast and uterus tissue the oestrogenic effects are mediated by ERα. The distribution of the ERs opens up the possibility to target specific tissues and thereby avoid certain negative effects of the classical estrogen pathway [20]. As selective oestrogen receptor modulators (SERMs) compounds, phytoestrogens may be considered as a therapeutic option in the prevention of osteoporosis [21], because these plant hormones can mimic the endogenous estrogens but lack the adverse side effects of HRT [5, 6].

Isoflavones make up the most common and well-known form of phytoestrogens, and in particular isoflavones (genistein and daidzein) from soy have received considerable attention in the management of postmenopausal bone loss [10, 22, 23]. Although the relative affinity of all isoflavones to the ER is lower than for estradiol, they can induce conformational changes that result in transcription activation. When absorbed into the body, phytoestrogens are able to behave similarly to weak natural estrogen; however ER binding can result in both agonist and antagonist actions. In the bone tissue an agonist activity is preferable as low levels of natural oestrogen will lead to weakened activity. In vitro and animal studies have revealed that phytoestrogens can enhance bone formation and increase bone mineral density and levels of alkaline phosphatase, osteocalcin, osteopontin, and α1(I) collagen. Furthermore, phytoestrogens are shown to suppress the rate of bone resorption and enhance bone formation rate [13, 24]. A large array of variables is known to influence bioavailability, metabolism, and ultimately physiological effects of phytoestrogens. In vitro and animal studies have suggested that phytoestrogens can have a significant effect on oestrogen-sensitive tissues, but the results from human clinical trials remain inconsistent [10].

Red clover (RC) contains phytoestrogens (i.e., isoflavones: formononetin, biochanin A, genistein, and daidzein), which bind to the estrogen receptors and can elicit a weak agonist, antagonist, or partial agonist antagonist response. The effect depends on the compound and the target tissue. The isoflavones are activated when the glucose residue is removed by the bacterial enzymes in the gastrointestinal flora. Thus, the bioavailability of phytoestrogens is particularly dependent on the bacterial flora, which varies considerably between individuals [10]. Unlike soy, RC has a high content of both formononetin and biochanin A, and studies in ovariectomised rat models have shown that formononetin contributes to bone formation process by stimulation differentiation of osteoblasts [14, 15, 25]. In addition formononetin has a higher estrogenic activity than daidzein [26]. Biochanin A has been demonstrated to induce a reduction in resorption of bone at the femoral neck when given to ovariectomised rats [27].

The study is, to our knowledge, the first to investigate the effect of daily consumption of a novel RC extract (rich in isoflavones due to the new fermentation process) which can help maintain bone mineral density, as determined by bone mineral density via DEXA scans, inflammatory status, and cardiovascular health in healthy menopausal women.

2. Subjects and Methods

2.1. Study Design. The study was conducted according to the guidelines in the Declaration of Helsinki and approved by the Danish Ethical Committee (M-20110267) and the Danish Data Protection Agency. According to the International Committee of Medical Journal Editors, the study protocol was registered at ClinicalTrials.gov (NCT02028702). The study was carried out as a 3-month, randomized, double-blinded, parallel designed trial. The primary endpoint was change in frequency and intensity of hot flashes, sleep disturbances, and flush related sweat (to be published elsewhere). Secondary endpoints were change in BMD as assessed by DXA, change in the levels of C-terminal telopeptide of type I collagen (CTx), blood pressure, and inflammatory markers.

The study involved two arms (Figure 1):

1. Red group: active treatment (RC extract),
2. Blue group: placebo.

The RC extract and placebo were handed out once every two weeks followed by a verbal meeting to ensure the participants compliance during the project. Participants in each group received a daily dose of 150 mL (75 mL in the morning and 75 mL in the evening) extract or equivalent dose of placebo equating to an approximate total of 13.5 liters over 90 days. During each extract collection day, each participant received either RC extract or placebo as required, approximately 2–4 litres per visit as necessary (accounting for losses). The participants would return empty 2-litre containers, which were collected by the research team as a measure for compliance. RC extract and placebo were packed in identical sealed brown cardboard cartons and marked with a red or blue cross, corresponding to either the red or blue group. The participants would incorporate the study extract into their normal habitual morning and evening diet. Both participants and research team were blinded to the content of the cartons throughout the study process. Participants were randomized, by computer generation, at the initiation of the study, but were not informed about their randomization allocation; however they were all required to consume 150 mL extract or equivalent placebo daily. The research team was
also blinded and the active or the placebo group was revealed after the study period to both participants and researchers.

2.2. Participant Recruitment and Screening. Participants were recruited from the general population in the Northern Denmark Region via press release and by advertisement within the local paper. Interested women were screened for eligibility by telephone at first, and if they met the inclusion criteria, they were invited to the clinic for a screening visit. The screening visit consisted of an extended interview followed by a blood sample. Basic anthropometric measurements were also recorded. The inclusion criteria were as follows: women with acknowledged problems with menopausal symptoms (>5 hot flushes per day; FSH level ≥35 UI/L; 40–65 years of age; BMI 20–40 kg/m²; and having a reported variable cycle length of >7 days different from normal. The exclusion criteria were as follows: participation in other clinical trials within the last 6 months; cardiovascular, chronic liver, thyroid, or kidney diseases; a history of cancer; a disease or condition, which may influence the participants ability to follow the study protocol; alcohol or drug abuse; use of hormonal contraceptives within the last 3 months; reported excessive dietary intake of isoflavone-rich foods; and finally blood pressure above 160/110 mmHg.

Participants provided written informed consent prior to enrolment into the trial and eligibility or exclusion was assessed by the research team based on the screening visit and the following results.

122 women underwent the screening visit, but only 62 women met the inclusion criteria and were enrolled in the study. One participant dropped out due to personal reasons, and another participant was excluded during the medical exam due to undisclosed information regarding her physiological status. A total of 60 women successfully completed the trial (Figure 2).

The participants were instructed to keep physical activity, smoking, and drinking habits constant and were told to maintain their normal diet and finally to abstain from any change in intake of nutritional supplements during the study period.

2.3. Study Assessments. The study included measurements of body composition, BP, fasting plasma samples, and DEXA scans. It was carried out at Center for Clinical Research, Vendsyssel Hospital, Aalborg University. Study researchers met the participants once every 2 weeks for extract dispensing and to perform motivational interviews, monitor compliance, and discuss any individual difficulties that might have occurred. Before the intervention and at weeks 6 and 12 a thorough questionnaire on dietary intake, exercise habit, alcohol and tobacco use, and lifestyle choices was used to ensure no alterations in the participant’s lifestyles during the intervention period.

Body Composition. Before the intervention and at week 12 standing height, weight (participants lightly clothed), and waist circumferences were measured.

Blood Pressure. 24-hour blood pressure measurements were performed before the intervention and at week 12 using a Spacelab monitor (Spacelabs Medical, Redmond, WA). The participants would come into the clinic in the morning and a trained study researcher would apply the blood pressure monitor to the right upper arm. The monitor was preprogrammed to measure the blood pressure hourly [28], and the participant was given a thorough oral instruction not
to move or talk during the measurements and relax their arms in an extended position during measurements. The participants were also given a form to write down any unusual activity during the 24 hours of measurements as well as their individual bedtimes. Participants were advised that they could carry out their usual activities but avoid strenuous exercise. Daytime was defined as measurements from 6:00 h–23:00 h, and night-time was within the timeframe of 23:00 h to 6:00 h.

Fasting plasma samples were collected at weeks 0 and 12. The participants would come into the clinic after an overnight fast and submit a blood sample after which they were offered breakfast.

Measurements of BMD in all participants were assessed by DEXA at baseline (week 0) and after the 12-week study period (week 12). All scans were performed by a trained radiographer using the XR-800 DEXA scanner (Norland Cooper, Surgical, USA, illuminates software version 4.2.4). The participants would come into the Orthopedic Department at the hospital and each scan lasted for 20 min. During this time, measurements of both bone mineral content in grams (BMC) and bone mineral density (g/cm

2.4. Biochemical Analysis. A fasting blood sample was collected at weeks 0, 6, and 12 using an evacuated-tube system and transferred to EDTA or lithium heparin evacuated tubes, temporarily stored on ice, and centrifuged at 4°C at 3500 g within 30 min. Plasma was then separated into aliquots and stored at −80°C. All samples from each subject were analyzed within one batch to reduce interbatch variation after study completion. All laboratory analyses were blinded, and all analytic procedures were carried out in accordance with the manufacturer’s instructions.

As a marker of bone resorption we analyzed C-terminal telopeptide of type 1 collagen (CTX) in plasma before and after the study period. The analysis is a standard laboratory method (sandwich immunometric assay, CV 5%) at the Department of Clinical Biochemistry (Aarhus University Hospital, Aarhus, Denmark).

Plasma cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, and IFN-γ) were measured using the Precision Pro Human Cytokine Assay (Bio-Rad, Hercules, CA, USA), according to the manufacturer’s instructions. Detection limits were below 1 pg/mL with an intra- and interassay CV below 10% and 15%, respectively. The responses were analyzed using the BioPlex Manager 6.0 software (Bio-Rad).

2.5. Red Clover Extract. The RC extract was produced and provided by Herrens Mark v/Michael Mohr Jensen, Nørre, Aaby, Denmark. Red clover crops were harvested approximately 6–8 months before being used in the study. Post-harvest processing requires the plant material to be transported to rust-free drums. Following this step, the RC mass is pressed and the resulting extract is pumped into large tanks where it is stored at 3–5°C. Aqueous extracts are left within the tanks, and lactic acid bacteria are added to the RC extract to induce fermentation for 6 months. During storage, the fermenting extract is routinely moved to a new tank every 6–8 weeks, allowing the pH to gradually fall, and the end pH of the extract lies at 4, which helps preserve the extract. The novel patented fermentation process (PA 2013/00233DK) is integral for the hydrolysis of isoflavone glycoside and glycoside compounds, which improve the bioavailability of the plant derived phytoestrogens.

In order to improve the likability and acceptability of the RC extract, a natural calorie-free sweetener stevia and a natural sugar-free raspberry/orange flavour were added. Specifically, 90 litres of either water (placebo) or RC extract was sweetened with 18 g of stevia and 6.3 litres of raspberry/orange flavouring to improve the taste. Due to the brown colour of the RC extract, brown food colouring was also added to the water-based placebo to achieve likeness in appearance to RC extract. The placebo was a liquid indistinguishable from RC extract also containing stevia and sugar-free raspberry/orange flavour, which enabled blinding of the study for both participants and the research team.

The postfermentation isoflavone composition and quantification analysis of the final extract was performed by DB Lab (DB Lab A/S, Odense SØ, Denmark). Quantification of compounds was assessed using high performance liquid chromatography with ultraviolet and mass spectrometry detection in a Summit LC/MS system (Dionex Corporation, Idstein, Germany). Standards for four of the primary isoflavones (genistein, daidzein, formononetin, and biochanin A) and the latter two glycoside derivatives (ononin and sissotrin) were obtained from Sigma Aldrich Denmark A/S (Brøndby, Denmark).

Based on the analysis (Table 1) of the RC extract women in the active RC group were given a dose of 37.1 mg isoflavones per day, of which 33.8 mg was aglycones.

2.6. Statistical Analysis. Statistical analysis included all participants who completed the study and from which appropriate material was obtained. Data was analyzed using StataIC statistical software (version 11.2; StataCorp LP, College Station, Texas, USA), and graphs were created by GraphPad Prism version 4 (GraphPad Software Inc., San Diego, CA, USA). Normal distribution of the data was checked by QQ-plots and histograms for the two groups separately. Baseline comparisons were assessed by unpaired Student’s t-test, and absolute within-group changes from baseline were calculated after the 12-week study period and tested by paired t-test. Changes are presented as mean ± SEM. In all cases, p ≤ 0.05 was considered significant. Power calculations were made on primary menopausal related symptoms (frequency and intensity of hot flushes). The minimum number of participants was determined by power calculations to be 62 (31 in each group), assuming a reduction in percentage of women experiencing hot flushes by at least 15% (minimal clinically important difference determined by Lipovac et al. [29]). An expected drop-out rate is 15%, power is 80%, SD is 3.3, and level of significance is 5%.
3. Results

3.1. Baseline Characteristics. A total of 60 women completed the study, and after randomization, subjects in the two groups were comparable with respect to all measured baseline characteristics (Table 2). Average age was 52.5 (±0.5) years and average BMI was 25.7 (±0.57) kg/m² at baseline.

3.2. Extract Isoflavone Content. The results of the postfermentation isoflavone composition and quantification analysis revealed that the majority of the isoflavones were as aglycones, although total conversion was not achieved due to the presence of ononin and sissotrin glucosides (Table 1).

3.3. Bone Mass and Density. We found a significant intragroup decrease in femoral neck BMD after 12 weeks of intervention in both the RC group (−0.86 ± 0.42%, p < 0.05) and the placebo group (−1.40 ± 0.55%, p < 0.05). In the lumbar spine region only the placebo group experienced a significant decline in BMD of −1.4 (±0.40%, p < 0.01) whereas the RC group had a percentage increase of 0.18 (±0.72%, p > 0.05) after the 12 weeks (Figure 3).

In addition, a small decline in femoral neck BMC was apparent in both groups (Table 4). In the RC group mean decrease in femoral neck BMC was −1.07 (±0.47%, p < 0.05), whereas the mean decrease in femoral neck BMC in the placebo group was −0.85 (±0.51%, p > 0.05). As expressed by p values only the result from the RC group was statistically significant. Regarding lumbar spine BMC, no significant changes were observed (Table 4).

3.4. Biochemical Analysis. The bone resorption marker CTx increased by 1.17% (±5.95, p > 0.05) in the placebo group and decreased by −9.94 (±4.93, p > 0.05)% in the active RC group, but the within-group differences were not statistically significant.

3.5. Blood Pressure. The results from the 24-hour blood pressure (Table 3) reveal no significant changes in systolic or diastolic blood pressure.

3.6. Inflammation. No significant differences were found within groups regarding the analysed cytokines in the RC and placebo group (Table 5). No significant differences were observed between baseline values (week 0) in the two groups.

3.7. Compliance. Compliance measured as counting of the returned used empty 2-litre containers (8 in total per participant) showed a 100% compliance in both groups.
Table 2: The baseline characteristics for treatment group (RC) and placebo.

|                          | RC (n = 29) | Placebo (n = 31) | p valuea |
|--------------------------|------------|-----------------|----------|
| Age, years               | 52.65 (±0.85) | 52.28 (±0.42) | p > 0.05 |
| BMI                      | 26.01 (±0.97) | 25.45 (±0.60) | p > 0.05 |
| FSH, int.enh./L          | 72.74 (±4.88) | 72.07 (±4.85) | p > 0.05 |
| Family history of osteoporosis (yes/no) | 6/29 | 5/26 | — |
| DXA                      |             |                 |          |
| BMD lumbar spine, g/cm²  | 1.06 (±0.04) | 1.05 (±0.04) | p > 0.05 |
| BMD femoral neck, g/cm²  | 0.913 (±0.02) | 0.85 (±0.02) | p > 0.05 |
| BMC, lumbar spine, g     | 50.49 (±2.16) | 48.34 (±1.57) | p > 0.05 |
| BMC, femoral neck, g     | 4.31 (±0.13) | 4.09 (±0.09) | p > 0.05 |
| T-score, lumbar spine, SD| −0.23 (±0.39) | −0.36 (±0.23) | p > 0.05 |
| T-score, femoral neck, SD| −0.06 (±0.20) | −0.57 (±0.17) | p > 0.05 |
| Biochemical marker       |             |                 |          |
| Ctx ng/mL                | 0.48 (±0.05) | 0.54 (±0.03) | p > 0.05 |
| 24-hour blood pressure   |             |                 |          |
| (i) Systolic mmHg        | 125.0 (±1.89) | 124.5 (±2.21) | p > 0.05 |
| (ii) Diastolic mmHg      | 78.9 (±1.36) | 78.2 (±1.26) | p > 0.05 |

a Representing p value between groups at baseline. Data are presented as mean (±SEM).

Table 3: Systolic and diastolic 24-hour blood pressure before (week 0) and after (week 12) the intervention in the two groups, RC and placebo.

|                      | Week 0         | Week 12        | p valuea | Week 0         | Week 12        | p valuea |
|----------------------|----------------|----------------|----------|----------------|----------------|----------|
| 24-hour BP: systolic (mmHg) | 125.0 (±1.89) | 122.6 (±2.17) | p > 0.05 | 124.5 (±2.21) | 122.1 (±2.23) | p > 0.05 |
| 24-hour BP: diastolic (mmHg) | 78.9 (±1.36) | 77.1 (±1.40) | p > 0.05 | 78.2 (±1.26) | 77.3 (±1.43) | p > 0.05 |

a Representing p value within-group differences between week 0 and week 12. Data are presented as mean (±SEM).

Table 4: BMC at lumbar spine and femoral neck before (week 0) and after (week 12) the intervention in the two groups, RC and placebo.

|                      | Week 0         | Week 12        | p valuea | Week 0         | Week 12        | p valuea |
|----------------------|----------------|----------------|----------|----------------|----------------|----------|
| BMC: lumbar spine, g | 50.49 (±2.16) | 50.26 (±2.07) | p > 0.05 | 48.34 (±1.57) | 48.89 (±1.77) | p > 0.05 |
| BMC: femoral neck, g | 4.312 (±0.13) | 4.263 (±0.13) | p < 0.05 | 4.087 (±0.10) | 4.056 (±0.10) | p > 0.05 |

a Representing p value within-group differences between week 0 and week 12. Data are presented as mean (±SEM).

Table 5: Inflammatory markers before (week 0) and after (week 12) the intervention in the two groups, RC and placebo.

|                      | Week 0         | Week 12        | p valuea | Week 0         | Week 12        | p valuea |
|----------------------|----------------|----------------|----------|----------------|----------------|----------|
| IL-1β, pg/mL         | 16.8 (±0.9)    | 16.6 (±0.9)    | p > 0.05 | 18.3 (±1.2)    | 15.9 (±1.1)    | p > 0.05 |
| IL-2, pg/mL          | 93.9 (±3.7)    | 93.4 (±4.2)    | p > 0.05 | 103.3 (±5.7)   | 94.9 (±6.6)    | p > 0.05 |
| IL-4, pg/mL          | 13.5 (±0.7)    | 13.3 (±0.7)    | p > 0.05 | 15.2 (±0.9)    | 13.4 (±1.0)    | p > 0.05 |
| IL-5, pg/mL          | 101.1 (±6.8)   | 107.5 (±6.8)   | p > 0.05 | 104.4 (±7.9)   | 97.4 (±8.0)    | p > 0.05 |
| IL-6, pg/mL          | 21.5 (±0.9)    | 22.54 (±1.2)   | p > 0.05 | 25.0 (±1.6)    | 23.2 (±1.6)    | p > 0.05 |
| IL-10, pg/mL         | 18.4 (±0.9)    | 17.4 (±0.8)    | p > 0.05 | 19.6 (±1.0)    | 18.1 (±1.1)    | p > 0.05 |
| IL-12, pg/mL         | 18.8 (±0.9)    | 18.0 (±0.9)    | p > 0.05 | 20.5 (±1.1)    | 18.5 (±1.3)    | p > 0.05 |
| IL-13, pg/mL         | 15.5 (±0.9)    | 16.0 (±0.9)    | p > 0.05 | 17.2 (±1.1)    | 15.5 (±1.1)    | p > 0.05 |
| IFN-gamma, pg/mL     | 33.1 (±1.6)    | 32.3 (±1.6)    | p > 0.05 | 35.5 (±1.8)    | 35.1 (±2.1)    | p > 0.05 |

a Representing p value within-group differences between week 0 and week 12. Data are presented as mean (±SEM).
4. Discussion

In this randomized, placebo-controlled intervention study, which included 60 healthy menopausal women, we found that a daily supplement of red clover extract containing isoflavones, mainly in the aglycone form, had positive effect on bone health. The spinal BMD, T-score, and CTx levels all improved in the group receiving the active RC supplement, but no effects were found on inflammatory markers and blood pressure. The isoflavones used in our study were derived from red clover and found in the extract product after it had been processed by a novel patented method.

Decline in bone mass will naturally occur during menopause due to decrease in estrogen production. Women reporting vasomotor symptoms are associated with having an even lower BMD than those who do not experience symptoms [30, 31]. As the first and most prominent stage of accelerated bone resorption occurs during menopause, women during this period may provide a better test group for therapies targeting bone mineral resorption as the higher BMD resorption may make them more sensitive to beneficial treatments. The average T-score at baseline in both groups was for both femoral neck and lumbar spine below 0, meaning that the BMD in the bones were lower than in a healthy 30-year-old woman. Osteopenia is diagnosed when the T-score is between −1 and −2.5 [32], so looking at the participants as a combined group, their mean T-scores reveal that they did not have osteopenia. With the average age of the participants being in their early fifties, it was predictable that their T-score was negative. We saw a large percentage decline in the femoral neck T-score in the placebo group, meaning that their bone strength declined over the intervention period. The opposite was seen in the RC treated group, where the femoral neck T-score increased over the 12 weeks.

DEXA scan was performed in both lumbar spine (L2–L4) and femoral neck area, but the greatest effect on bone status was seen in the lumbar spine. The decline in estrogen production during menopause might first present low BMD in lumbar spine before the femoral neck supplementation in estrogen or even phytoestrogens may benefit the lumbar spine in the short term to a greater degree when compared to the femoral neck. The lumbar spine contains higher trabecular tissue in contrast to the femoral neck and could retain a shorter response time to treatment than the femoral neck. A treatment window of three months may only have enabled attenuation to occur in certain locations with faster remodelling rates; for example, spinal remodelling is shown to occur at a higher rate than at the hip, as is apparent in the present study [33, 34]. In the lumbar spine the anticipated natural decline in BMD over time was observed in the placebo group and results showed a significant decline in BMD. Interestingly, the mean lumbar spine BMD change in the treatment group from baseline to week 12 of intervention was slightly positive, which demonstrated that treatment with red clover extract had an attenuating effect on bone resorption. Perhaps giving a longer term treatment might even stimulate bone formation and/or have had a greater effect on the hip.

One peculiar finding within the study was that spinal BMC in the placebo group did not significantly decrease with spinal BMD. We observed a nonsignificant increase of spinal BMC in the placebo group; however similar result has also been observed in other studies, supporting the theory that BMC is not directly proportional to bone area. As a consequence, changes in bone area and BMC can occur independently of one another; however, the interpretation and relationship of BMC and BMD at skeletal sites needs to be further investigated. It is worth considering that given a constant BMC, any increase to areal bone size will decrease the BMD [35, 36]. In our study, data suggests that the placebo group developed more porous bone structures, which have the same BMC but are less densely assembled together as a consequence of resorption phase bias. Moreover, other studies have shown that the effect of soy isoflavones on BMC is greater in the longer duration since menopause, indicating that a more stringent control of our participants in selecting for menopausal stage may yield better results when assessing BMC [37].

Despite the large numbers of studies of isoflavones derived from soy and partly red clover, due to the heterogeneity of the human trials, differences in both the types of isoflavones used and the form in which they were provided (glycoside compared to aglycone), differences in isoflavone metabolism, and so forth, it is still not clear which specific products and what dose will provide the best health benefits regarding bone metabolism effects [38–43]. A number of studies have attempted to address whether isoflavones can prevent and/or treat menopausal and postmenopausal bone loss. Most of the studies conclude that current evidence is not sufficient to make recommendations regarding the effects of isoflavones on bone health [10, 44–46].

In plants, isoflavones are inactive when present in the bound form as glycosides, but when the sugar residue is removed these compounds become activated and only the aglycones can be absorbed [47]. During the preparations of the RC extract used in this study, adding of lactic acid bacteria and the processing for 6 months give a high level of isoflavones in aglycone form contributing to a higher bioavailability and hence a higher physiological effect. However, the bioavailability of phytoestrogens also depends largely on the intestinal flora because bacterial enzymes in the intestine transform isoflavones into different metabolites. Approximately one-third of humans microbial gut flora also naturally transform daidzien (aglycone form of daidzin) into equol, which is adsorbed in the intestine and is 10–100-fold more estrogenic than both daidzien and genistien [48]. Equol-producers were not categorized in our study but in another clinical trial investigating the effect of soy isoflavones on menopausal women and their analyses on a subgroup of equol producing women showed no benefit when compared to nonequol producing menopausal women [49].

Participants did not receive the entire dose of daily RC all at once but one dose in the morning and one in the evening. This might give a higher uptake in the gastrointestinal tract as the body has an upper limit regarding the absorption rate of isoflavones and their derived metabolites. If the dose was further spread out during the day, there might be
an even higher uptake, but this might be too inconvenient to the participants and could result in lower compliance. We also have no knowledge as to which isoflavones or derived metabolites precisely induce positive health effect on the bones or the extent of synergistic effects. However, RC has a high content of formononetin (Table 1) and studies have shown that formononetin has positive effects on bone health.

It is recommended that the duration of the interventions using bone formation markers as an indicator of bone turnover last for at least 6 months [50]. Due to the relative short timeframe of our study, we choose only to look at CTx, a bone resorption marker. We found a nonsignificant trend for decreased plasma CTx, in the group receiving the active red clover extract, suggesting that bone resorption is decreased. The placebo group experienced no changes in CTx levels, which indicates that they experience no changes with respect bone resorption.

No changes were found in regard to 24-hour blood pressure in either RC or placebo group, but as seen in Table 2 the blood pressure of the participants was within the normal range with no or very little room for improvement. It might have been better to measure changes in total vascular resistance and arterial stiffness as opposed to blood pressure in participants with an already healthy cardiovascular profile [51].

Oestrogen also has an effect on the synthesis and activity of various inflammatory cytokines, and a lack of oestrogen therefore leads to increased levels of inflammatory cytokines [52, 53]. Changes in level of low-grade inflammation could also have an effect on bone metabolism; however, no effect on inflammation markers could be demonstrated after 12 weeks of intervention with RC extract. The positive effect of red clover on bone health in this study could not be explained by anti-inflammatory effects. Interestingly, this suggests that a component of isoflavone action on bone may be independent of inflammation markers.

Regarding the safety of the active group with a daily intake of 371 mg isoflavones, recently a 2-year trial accessing the safety issues related to a high isoflavone intake (80–120 mg soy hypocotyls isoflavones) concluded that daily supplementation for 2 years is associated with minimal risk in healthy menopausal women [54]. No severe events were observed in our study during the 12 weeks of intervention.

Age, race, and dietary components like carbohydrate and fat content in the diet, type of dietary fat, presence of probiotics, and so forth all influence the isoflavone metabolism [55]. The participants were instructed not to change anything regarding lifestyle and dietary habits in the intervention period, and questionnaires confirm that the eating pattern is similar before and during the study period. None of the participants had high intake of isoflavone containing foods as this was part of the inclusion criteria.

Body weight plays an important role in the rate of menopausal bone loss, because rates of bone loss are 35% to 55% slower in women with higher BMI. Increased production of estrogens by adipose tissue may contribute to the association between BMD and body weight. Our participants had a mean BMI revealing that they were normal weight to slightly overweight. However, participants were not overweight enough for it to have any influence on the BMD [30].

There is a wide disparity in BMD, bone turnover, and fracture incidence across ethnic groups [56, 57], but the women in our study were all Caucasian from the northern part of Denmark, so this was not a factor we had to take into consideration.

The strengths of the study include the design, a randomized, placebo-controlled, double-blinded study with a good adherence rate. The participants had a great interest in the study due to personal discomfort caused by their menopausal status, which contributed to the low drop-out rate and 100% compliance according to the returned boxes. The RC extract and placebo intake were very convenient for the participants, and they were able continue with their normal life during the intervention period. The method used for diagnosing osteoporosis is dual-energy X-ray absorptiometry (DEXA) scan, which can determine bone density at whole body level or at specific areas such as the hip and lower spine, the typical and most vulnerable areas of the body. The same diagnostic methods as used in the clinic and doctors standard practice [8] were utilised to characterize and diagnose osteoporosis which were used in this study.

The short intervention period prevents us from drawing any conclusions about the long-term effect of red clover on bone metabolism, but this would be interesting to look into in the future.

RC extract intake is convenient and can easily be incorporated into everyday life. In therapeutic use, RC extract might be categorized as a preventive treatment or a prophylactic preparation regarding bone status and menopausal symptoms.

Our study showed that healthy nonosteopenic women had a beneficial effect on bone status when consuming the RC extract. Since the treatment of osteoporosis and osteoporotic fractures has a huge impact on individual recovery and the national health budget [8], it is important to have a greater focus on prevention of bone loss in relation to postfactum treatment.

Further studies of longer durations comprising populations at risk of osteoporosis are needed to confirm these positive effects of red clover extract, but a long-term study is currently being conducted.

To conclude, intervention of daily consumption of RC extract with a high content of bioavailable aglycone isoflavones over a three-month period was found to have a beneficial effect on bone health based on measurements of BMD, T-score, and CTx levels in healthy menopausal women, when compared to placebo. These changes were apparent in both the lumbar spine and the femoral neck regions. Combining the CTx data with the BMD analyses strongly indicates that red clover decreases osteoclast activity and promotes osteoblast activity, leading to increase in BMD in the short term. However, no changes in 24-hour blood pressure or markers of inflammation status were found.
Conflict of Interests

The authors declare that A. C. Thorup, M. N. Lambert, P. B. Jeppesen, and M. M. Jensen (Herrens Mark) are coinventors of the patent (PA 2013/00233DK) with the title “Product comprising red clover extract and methods for producing the same.” All rights are held by the company Herrens Mark. The authors have no economic interest in the company. Herrens Mark had no influence on the study design, implementation, or subsequent analyses.

Acknowledgments

The authors thank Conni Biehl Christiansen, Britt Bloch Nielsen, and Ulrik Bandrup at Hospital Vendsyssel. The authors also want to thank Ulla Birkelyng, Charlotte Jensen, and Minna Christensen for assistance with the scans and Peter Hindersson and Trine Kristensen from the Department of Clinical Biochemistry. Also thanks are due to Peter Hindersson and Trine Kristensen from the Department of Clinical Biochemistry. Also thanks are due to Ulrik Bandrup at Hospital Vendsyssel. The authors thank Conni Biehl Christiansen, Britt Bloch Nielsen, and Ulrik Bandrup at Hospital Vendsyssel. The authors also want to thank Ulla Birkelyng, Charlotte Jensen, and Minna Christensen for assistance with the scans and Peter Hindersson and Trine Kristensen from the Department of Clinical Biochemistry. Also thanks are due to Herrens Mark for providing the red clover extract. The study was funded by the Danish Council for Strategic Research (MaxVeg 09-067129).

References

[1] P. Andreopoulou and R. S. Bockman, “Management of postmenopausal osteoporosis,” Annual Review of Medicine, vol. 66, pp. 329–342, 2015.
[2] J. Justesen, K. Stenderup, E. N. Ebbesen, L. Moskilde, T. Steiniche, and M. Kassem, “Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis,” Biogerontology, vol. 2, no. 3, pp. 165–171, 2001.
[3] D. P. Kiel, D. T. Felson, J. J. Anderson, P. W. F. Wilson, and M. A. Moskowitz, “Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study,” The New England Journal of Medicine, vol. 317, no. 19, pp. 1169–1174, 1987.
[4] J. A. Cauley, D. G. Seeley, K. Ensrud, R. Ettinger, D. Black, and S. R. Cummings, “Estrogen replacement therapy and fractures in older women,” Annals of Internal Medicine, vol. 122, no. 1, pp. 9–16, 1995.
[5] J. E. Rossouw, G. L. Anderson, R. L. Prentice et al., “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial,” The Journal of the American Medical Association, vol. 288, no. 3, pp. 321–333, 2002.
[6] F. Cosman, S. J. de Beur, M. S. LeBoff et al., “Clinician’s guide to prevention and treatment of osteoporosis,” Osteoporosis International, vol. 25, no. 10, pp. 2359–2381, 2014.
[7] C. MacLean, S. Newberry, M. Maglione et al., “Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis,” Annals of Internal Medicine, vol. 148, no. 3, pp. 197–213, 2008.
[8] E. Hernlund, A. Svedbon, M. Ivergård et al., “Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA),” Archives of Osteoporosis, vol. 8, article 136, 2013.
[9] S. Das and J. C. Crockett, “Osteoporosis—a current view of pharmacological prevention and treatment,” Drug Design, Development and Therapy, vol. 7, pp. 435–448, 2013.
[10] V. S. Lagari and S. Levis, “Phytoestrogens for menopausal bone loss and climacteric symptoms,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 139, pp. 294–301, 2014.
[11] V. S. Lagari and S. Levis, “Phytoestrogens in the prevention of postmenopausal bone loss,” Journal of Clinical Densitometry, vol. 16, no. 4, pp. 445–449, 2013.
[12] M. J. Ornstrup, T. Harslof, T. N. Kjær, B. L. Langdahl, and S. B. Pedersen, “Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 12, pp. 4720–4729, 2014.
[13] S. S. Chiang and T. M. Pan, “Beneficial effects of phytoestrogens and their metabolites produced by intestinal microflora on bone health,” Applied Microbiology and Biotechnology, vol. 97, no. 4, pp. 1489–1500, 2013.
[14] I. Kaczmarczyk-Sedlak, W. Wojnar, M. Zych, E. Ozimina-Kamińska, J. Taranowicz, and A. Siwek, “Effect of formononetin on mechanical properties and chemical composition of bones in rats with ovariectomy-induced osteoporosis,” Evidence-Based Complementary and Alternative Medicine, 2013, Article ID 457052, 10 pages, 2013.
[15] K. Srivastava, A. M. Tyagi, K. Khan et al., “Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis,” Phytotherapy, vol. 20, no. 6, pp. 470–480, 2013.
[16] K. D. R. Setchell, “Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones,” The American Journal of Clinical Nutrition, vol. 68, no. 6, pp. 1335S–1346S, 1998.
[17] T. Löránd, E. Vigh, and J. Garai, “Hormonal action of plant estrogen receptor β1 and estrogenic compounds: phytoestrogens and xenoestrogens,” Current Medicinal Chemistry, vol. 17, no. 30, pp. 3542–3574, 2010.
[18] L. Pilsková, I. Riecanský, and F. Jagla, “The physiological actions of isoflavone phytoestrogens,” Physiological Research, vol. 59, no. 5, pp. 651–664, 2010.
[19] B. G. Chrzan and P. G. Bradford, “Phytoestrogens activate estrogen receptor β1 and estrogenic responses in human breast and bone cancer cell lines,” Molecular Nutrition and Food Research, vol. 51, no. 2, pp. 171–177, 2007.
[20] E. Poluzzi, C. Piccinini, E. Raschi, A. Rampa, M. Recanatini, and F. de Ponti, “Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective,” Current Medicinal Chemistry, vol. 21, no. 4, pp. 417–436, 2014.
[21] B. S. Komm and A. A. Chines, “An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis,” Maturitas, vol. 71, no. 3, pp. 221–226, 2012.
[22] C. Castelo-Branco and M. J. Cancelo Hidalgo, “Isoflavones: effects on bone health,” Climacteric, vol. 14, no. 2, pp. 204–211, 2011.
[23] A. Atmaca, M. Kleerekoper, M. Bayraktar, and O. Kucuk, “Soy isoflavones in the management of postmenopausal osteoporosis,” Menopause, vol. 15, no. 4, pp. 748–757, 2008.
[24] A. V. Sirotnik and A. H. Harrah, “Phytoestrogens and their effects,” European Journal of Pharmacology, vol. 741, pp. 230–236, 2014.
[25] A. M. Tyagi, K. Srivastava, A. K. Singh et al., “Formononetin reverses established osteopenia in adult ovariectomized rats,” Menopause, vol. 19, no. 8, pp. 856–863, 2012.
[26] J. K. Pru, "The bone-promoting actions of formononetin in established osteopenia," Menopause, vol. 19, no. 8, pp. 843–844, 2012.

[27] S.-J. Su, Y.-T. Yeh, and H.-W. Shyu, "The preventive effect of biochanin a on bone loss in ovariectomized rats: involvement in regulation of growth and activity of osteoblasts and osteoclasts," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 594857, 10 pages, 2013.

[28] M. Sun, J. Tien, R. Jones, and R. Ward, "A new approach to reproducibility assessment: clinical evaluation of SpaceLabs Medical oscillometric blood pressure monitor," Biomedical Instrumentation & Technology, vol. 30, no. 5, pp. 439–448, 1996.

[29] M. Lipovac, P. Chedraui, C. Gruenhut et al., "The effect of red clover isoflavone supplementation on vasomotor and menopausal symptoms in postmenopausal women," Gynecological Endocrinology, vol. 28, no. 3, pp. 203–207, 2012.

[30] J. S. Finkelstein, S. E. Brockwell, V. Mehta et al., "Bone mineral density changes during the menopause transition in a multithnic cohort of women," The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 3, pp. 861–868, 2008.

[31] G.-C. M. Gast, D. E. Grobbee, V. J. M. Pop et al., "Vasomotor symptoms are associated with a lower bone mineral density," Menopause, vol. 16, no. 2, pp. 231–238, 2009.

[32] J. A. Kanis, E. V. McCloskey, H. Johansson, L. J. Melton III, and N. Khaltaev, "A reference standard for the description of osteoporosis," Bone, vol. 42, no. 3, pp. 467–475, 2008.

[33] J. M. Kling, B. L. Clarke, and N. P. Sandhu, "Osteoporosis prevention, screening, and treatment: a review," Journal of Women’s Health, vol. 23, no. 7, pp. 563–572, 2014.

[34] S. M. Potter, J. A. Baum, H. Teng, R. J. Stillman, N. F. Shay, and J. W. Erdman Jr., "Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women," The American Journal of Clinical Nutrition, vol. 68, no. 6, pp. 1378S–1379S, 1998.

[35] A. Prentice, T. J. Parsons, and T. J. Cole, "Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants," The American Journal of Clinical Nutrition, vol. 60, no. 6, pp. 837–842, 1994.

[36] M. D. Van Loan, H. L. Johnson, and T. F. Barbieri, "Effect of weight loss on bone mineral content and bone mineral density in obese women," The American Journal of Clinical Nutrition, vol. 67, no. 4, pp. 734–738, 1998.

[37] Y.-M. Chen, S. C. Ho, S. S. H. Lam, S. S. S. Ho, and J. L. F. Woo, "Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial," Menopause, vol. 11, no. 3, pp. 246–254, 2004.

[38] T. Y. Tai, K. S. Tsai, S. T. Tu et al., "The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: A 2-year randomized double-blind placebo-controlled study," Osteoporosis International, vol. 23, no. 5, pp. 1571–1580, 2012.

[39] A. M. Kenny, K. M. Mangano, R. H. Abourizk et al., "Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial," The American Journal of Clinical Nutrition, vol. 90, no. 1, pp. 234–242, 2009.

[40] H. Marini, L. Minutoli, F. Polito et al., "Effects of the phyto-oestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized controlled trial," The American Journal of Clinical Nutrition, vol. 146, no. 12, pp. 839–847, 2007.

[41] S. Kreijkamp-Kaspers, L. Kok, D. E. Grobbee et al., "Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial," The Journal of the American Medical Association, vol. 292, no. 1, pp. 65–74, 2004.

[42] W. W. Wong, R. D. Lewis, F. M. Steinberg et al., "Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial," American Journal of Clinical Nutrition, vol. 90, no. 5, pp. 1433–1439, 2009.

[43] P. B. Clifton-Bligh, M.-L. Nery, R. J. Clifton-Bligh et al., "Red clover isoflavones enriched with formononetin lower serum LDL cholesterol—a randomized, double-blind, placebo-controlled study," European Journal of Clinical Nutrition, vol. 69, no. 1, pp. 134–142, 2015.

[44] K. Taku, M. K. Melby, S. M. Kurzer, S. Mizuno, S. Watanabe, and Y. Ishimi, "Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials," Bone, vol. 47, no. 2, pp. 413–423, 2010.

[45] K. Taku, M. K. Melby, N. Nishi, T. Omori, and M. S. Kurzer, "Soy isoflavones for osteoporosis: an evidence-based approach," Maturitas, vol. 70, no. 4, pp. 333–338, 2011.

[46] P. Wei, M. Liu, Y. Chen, and D.-C. Chen, "Systematic review of soy isoflavone supplements on osteoporosis in women," Asian Pacific Journal of Tropical Medicine, vol. 5, no. 3, pp. 243–248, 2012.

[47] A. Cassidy, " Dietary phyto-oestrogens: molecular mechanisms, bioavailability and importance to menopausal health," Nutrition Research Reviews, vol. 18, no. 2, pp. 183–201, 2005.

[48] H. Fang, W. Tong, L. M. Shi et al., "Structure—activity relationships for a large diverse set of natural, synthetic, and environmental estrogens," Chemical Research in Toxicology, vol. 14, no. 3, pp. 280–294, 2001.

[49] S. Levis, N. Strickman-Stein, P. Ganji-Azar, P. Xu, D. R. Doerge, and J. Krischer, "Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial," Archives of Internal Medicine, vol. 171, no. 15, pp. 1363–1369, 2011.

[50] Y. Nishizawa, T. Nakamura, H. Ohta et al., "Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)," Journal of Bone and Mineral Metabolism, vol. 23, no. 2, pp. 97–104, 2005.

[51] H. J. Teede, B. P. McGrath, L. DeSilva, M. Cehun, A. Fassoulakis, M. Brincat, and J. Calleja-Agius, "The role of cytokines in cardiovascular disease in menopause," Climacteric, vol. 15, no. 6, pp. 524–530, 2012.

[52] S. Akyol, S. A. Cidotlessnar, S. Purisa, and K. Aydinli, "Relationship between lymphocytes, IL2 and the hormones E2, LH, PRG and FSH in menopausal and postmenopausal women," The American Journal of Reproductive Immunology, vol. 66, no. 4, pp. 304–309, 2011.
[55] R. C. Poulsen and M. C. Kruger, “Soy phytoestrogens: impact on postmenopausal bone loss and mechanisms of action,” Nutrition Reviews, vol. 66, no. 7, pp. 359–374, 2008.

[56] J. S. Finkelstein, M.-L. T. Lee, M. Sowers et al., “Ethnic variation in bone density in premenopausal and early perimenopausal women: effects of anthropometric and lifestyle factors,” The Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 7, pp. 3057–3067, 2002.

[57] M. R. Sowers, H. Zheng, G. A. Greendale et al., “Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, pp. 2854–2863, 2013.